Morpholine-containing and piperazine-containing CXCR4 modulators and uses related thereto

A compound of Formula I or a pharmaceutically acceptable salt thereof,

• wherein W is CH2 or O;
• wherein Vis hydrogen, an optionally substituted C1-C4 alkyl, or an optionally substituted C1-C4 haloalkyl;
• wherein:
• (1) R1 is an optionally substituted C1-C4 alkyl, an optionally substituted C1-C4 haloalkyl, an optionally substituted C1-C4 alkenyl, an optionally substituted C1-C4 haloalkenyl, an optionally substituted carbocyclyl, or an optionally substituted halocarbocyclyl, or
• (2) R1 is an optionally substituted, bridging C1-C4 alkyl, an optionally substituted, bridging C1-C4 haloalkyl, an optionally substituted, bridging C1-C4 alkenyl, or an optionally substituted, bridging C1-C4 haloalkenyl, joining the carbon atom labeled by the “*” sign to form an optionally substituted heterocycle;
• wherein the pair of R8 and R9 is ═O or ═S;
• wherein R2, R3, R4, R5, R6, and R7 are independently hydrogen, halogen, amino, optionally substituted hydroxyl, optionally substituted alkyl, or optionally substituted haloalkyl;
• optionally wherein one or more of the following pairs—R2 and R3, R4 and R5, and R6 and R7—are independently ═O or ═S;
• and
• optionally wherein two of R2, R3, R4, R5, R6, and R7 joint together to form a bridge on the morpholine ring or a carbocycle or heterocycle that is connected to the morpholine ring in a spiro manner (i.e., the two rings are connected through a single common atom) or in a fused manner (i.e., the two rings share two adjacent atoms;
• in other words, the two rings share one covalent bond).